Navigation Links
SpectraScience, Inc. Retains Hayden Communications
Date:2/11/2008

SAN DIEGO, Feb. 11 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulltetin Board: SCIE), a San Diego based medical devices company, today announced that it has retained Hayden Communications, a New York based investor relations consulting firm to provide strategic investor relations services.

Jim Hitchin, Chief Executive Officer of SpectraScience, stated, "We have selected Hayden Communications because it has demonstrated expertise and resources that will enable us to more effectively develop and communicate our corporate message to the Street as we transition from an R&D focused business to the commercialization of our WavSTAT(TM) and LUMA(TM) product lines."

Brett Maas, Principal of Hayden Communications, stated "We are looking forward to working with SpectraScience. We are impressed with the company's products as well as the addressable market opportunity and demand for a more effective and less invasive pre-cancer detection offering. In addition, we think that its business model is compelling and believe that the timing is right to begin communicating this message to the investment community."

SpectraScience has filed for 60 patents worldwide on its WavSTAT(TM) Optical Biopsy System and LUMA(TM) cervical cancer imaging system that are used to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT and LUMA systems are currently approved by the FDA for detecting pre-cancer and cancer in the colon and cervix, and an application for detection in the throat ("Barrett's esophagus") is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT(TM) Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA clearance for sale in the U.S. and the CE Mark for the European Union, the WavSTAT(TM) system is the first commercially available product that incorporates this innovative technology for clinical use. The Company's recently acquired LUMA(TM) imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

Hayden Communications

Investor Relations

Todd Pitcher

(858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Assured Pharmacy Retains Empire Financial Group
2. Sunnylife Global Retains The Blaine Group For Investor Relations, Financial Public Relations
3. Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations
4. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
5. Genesis Technology Group Retains CCG Elite
6. The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR
7. QMed, Inc. Retains Lazard Middle Market
8. Big A Drug Stores, Inc. Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium, Big A, Camelot, Drug Fair and Drug Barn
9. Diagnostic Centers of America Retains NewsMark Public Relations to Showcase Its Rise as Only Medical Facility in South Florida With Worlds Most Advanced Cardiac Scanner
10. Leading Cosmetic Dermatologist, Peter G. Ballas II MD, Retains Kay Renz Public Relations to Promote his Practice and New Skincare Line
11. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
(Date:2/23/2017)... -- ... Research and Markets has announced the addition of the "Global Antifungal ... to their offering. The Global Antifungal Drugs Market is ... decade to reach approximately $12.8 billion by 2025. ... given segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... 2017  MiMedx Group, Inc. (NASDAQ: MDXG), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and Dental sectors of healthcare, today announced its ... ended December 31, 2016. Full Year 2016 ... 31% increase over full year 2015 revenue ...
Breaking Medicine Technology: